Skip Nav Destination
Issues
1 February 2011
-
Cover Image
Cover Image
Rapid restoration of tumor microvasculature and perfusion in esophageal cancer xenografts treated with a vascular disrupting agent. Kyse-30 tumors were analyzed two weeks after administration of one single dose of the immunoconjugate L19mTNFa. Microvessels were stained by anti-CD31 (red), whereas perfusion was evaluated by injection of Dextran-FITC 70 kDa (green). Nuclei were stained by TOPRO-3 (blue). For further details, please see Crescenzi and coworkers on page 447 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Review
Human Cancer Biology
Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis
Moriko Ito; Louise Barys; Terence O'Reilly; Sophie Young; Bella Gorbatcheva; John Monahan; Sabine Zumstein-Mecker; Peter F. Choong; Ian Dickinson; Philip Crowe; Christine Hemmings; Jayesh Desai; David M. Thomas; Joanna Lisztwan
Endogenous Versus Tumor-Specific Host Response to Breast Carcinoma: A Study of Stromal Response in Synchronous Breast Primaries and Biopsy Site Changes
Julie M. Wu; Andrew H. Beck; Lisa L. Pate; Daniela Witten; Shirley X. Zhu; Kelli D. Montgomery; Kimberly H. Allison; Matt van de Rijn; Robert B. West
Cancer Therapy: Preclinical
Forkhead Transcription Factor FOXO1 is a Direct Target of Progestin to Inhibit Endometrial Epithelial Cell Growth
Satoru Kyo; Junko Sakaguchi; Tohru Kiyono; Yutaka Shimizu; Yoshiko Maida; Yasunari Mizumoto; Noriko Mori; Mitsuhiro Nakamura; Masahiro Takakura; Kiyohiko Miyake; Masaru Sakamoto; Masaki Inoue
Imaging, Diagnosis, Prognosis
Longitudinal Investigation of Permeability and Distribution of Macromolecules in Mouse Malignant Transformation Using PET
Cecilie B. Rygh; Shengping Qin; Jai W. Seo; Lisa M. Mahakian; Hua Zhang; Roger Adamson; Jane Q. Chen; Alexander D. Borowsky; Robert D. Cardiff; Rolf K. Reed; Fitz-Roy E. Curry; Katherine W. Ferrara
Cancer Therapy: Clinical
Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer
Beatrice J. Edwards; Dennis W. Raisch; Veena Shankaran; June M. McKoy; William Gradishar; Andrew D. Bunta; Athena T. Samaras; Simone N. Boyle; Charles L. Bennett; Dennis P. West; Theresa A. Guise
A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
Ronan J. Kelly; Deborah Draper; Clara C. Chen; Robert W. Robey; William D. Figg; Richard L. Piekarz; Xiaohong Chen; Erin R. Gardner; Frank M. Balis; Aradhana M. Venkatesan; Seth M. Steinberg; Tito Fojo; Susan E. Bates
A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
Martijn P. Lolkema; Hendrik-Tobias Arkenau; Kevin Harrington; Patricia Roxburgh; Rosemary Morrison; Victoria Roulstone; Katie Twigger; Matt Coffey; Karl Mettinger; George Gill; T.R. Jeffry Evans; Johann S. de Bono
Modulation of Genetic and Epigenetic Biomarkers of Colorectal Cancer in Humans by Black Raspberries: A Phase I Pilot Study
Li-Shu Wang; Mark Arnold; Yi-Wen Huang; Christine Sardo; Claire Seguin; Edward Martin; Tim H.-M. Huang; Ken Riedl; Steven Schwartz; Wendy Frankel; Dennis Pearl; Yiqing Xu; John Winston, III; Guang-Yu Yang; Gary Stoner
Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors
R. Bagatell; C.E. Herzog; T.M Trippett; J.F. Grippo; G. Cirrincione-Dall; E. Fox; M. Macy; J. Bish; P. Whitcomb; A. Aikin; G. Wright; S. Yurasov; F.M. Balis; L. Gore
Predictive Biomarkers and Personalized Medicine
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
Astrid A.M. van der Veldt; Karel Eechoute; Hans Gelderblom; Jourik Gietema; Henk-Jan Guchelaar; Nielka P. van Erp; Alfons J.M. van den Eertwegh; John B. Haanen; Ron H.J. Mathijssen; Judith A.M. Wessels
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds